Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

被引：73
|
作者：
Boucau, Julie [1 ]
Uddin, Rockib [2 ]
Marino, Caitlin [1 ]
Regan, James [3 ]
Flynn, James P. [3 ]
Choudhary, Manish C. [3 ,4 ]
Chen, Geoffrey [2 ]
Stuckwisch, Ashley M. [2 ]
Mathews, Josh [2 ]
Liew, May Y. [2 ]
Singh, Arshdeep [2 ]
Reynolds, Zahra [2 ]
Iyer, Surabhi L. [2 ]
Chamberlin, Grace C. [2 ]
Vyas, Tammy D. [2 ]
Vyas, Jatin M. [2 ,4 ]
Turbett, Sarah E. [2 ]
Li, Jonathan Z. [3 ,4 ]
Lemieux, Jacob E. [2 ,4 ,5 ]
Barczak, Amy K. [1 ,2 ,4 ]
Siedner, Mark J. [2 ,4 ]
机构：
[1] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02215 USA
[3] Brigham & Womens Hosp, Boston, MA 02215 USA
[4] Harvard Med Sch, Boston, MA 02215 USA
[5] Broad Inst, Cambridge, MA 02138 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期
关键词：
COVID-19; therapeutics; anti-virals; nirmatrelvir-ritonavir; virology;
D O I：
10.1093/cid/ciac512
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log(10) copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.
引用
收藏
页码：E526 / E529
页数：4
相关论文
共 50 条
  • [1] Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19
    Anderson, Annaliesa S.
    Caubel, Patrick
    Rusnak, James M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (11): : 1047 - 1049
  • [2] Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy
    Cohen, Myron S.
    Brown, Elizabeth R.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (12) : 1672 - 1673
  • [3] Nirmatrelvir-Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation
    Lin, Christine Y.
    Cassidy, Arianna G.
    Li, Lin
    Prahl, Mary K.
    Golan, Yarden
    Gaw, Stephanie L.
    OBSTETRICS AND GYNECOLOGY, 2023, 141 (05): : 957 - 960
  • [4] Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment
    Epling, Brian P.
    Rocco, Joseph M.
    Boswell, Kristin L.
    Laidlaw, Elizabeth
    Galindo, Frances
    Kellogg, Anela
    Das, Sanchita
    Roder, Allison
    Ghedin, Elodie
    Kreitman, Allie
    Dewar, Robin L.
    Kelly, Sophie E. M.
    Kalish, Heather
    Rehman, Tauseef
    Highbarger, Jeroen
    Rupert, Adam
    Kocher, Gregory
    Holbrook, Michael R.
    Lisco, Andrea
    Manion, Maura
    Koup, Richard A.
    Sereti, Irini
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) : 573 - 581
  • [5] Nirmatrelvir-ritonavir for COVID-19
    McDonald, Emily G.
    Lee, Todd C.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (06) : E218 - E218
  • [6] Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19
    Buxeraud, Jacques
    Faure, Sebastien
    Fougere, Edouard
    ACTUALITES PHARMACEUTIQUES, 2020, 61 (617): : 10 - 12
  • [7] Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19)
    Toure, Bineta B.
    Panakam, Aisvarya
    Johns, Sarah L.
    Butler, Sharlay K.
    Tuomala, Ruth E.
    Diouf, Khady
    OBSTETRICS AND GYNECOLOGY, 2024, 143 (02): : 273 - 276
  • [8] Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment
    Carlin, Aaron F.
    Clark, Alex E.
    Chaillon, Antoine
    Garretson, Aaron F.
    Bray, William
    Porrachia, Magali
    Santos, AsherLev T.
    Rana, Tariq M.
    Smith, Davey M.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E530 - E532
  • [9] Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons
    Ranganath, Nischal
    O'Horo, John C.
    Challener, Douglas W.
    Tulledge-Scheitel, Sidna M.
    Pike, Marsha L.
    O'Brien, R. Michael
    Razonable, Raymund R.
    Shah, Aditya
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E537 - E539
  • [10] Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
    Marchetti, Giulia
    Rovito, Roberta
    Bono, Valeria
    Bonara, Paola
    Bai, Francesca
    Monforte, Antonella d'Arminio
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (05) : 660 - 662
12345